CLRP.F Stock Overview
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clarity Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.15 |
| 52 Week High | AU$2.35 |
| 52 Week Low | AU$0.48 |
| Beta | 1.28 |
| 1 Month Change | 17.81% |
| 3 Month Change | 37.82% |
| 1 Year Change | 315.62% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 252.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLRP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 27.2% | 3.0% | -0.7% |
| 1Y | 315.6% | 12.5% | 22.8% |
Return vs Industry: CLRP.F exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: CLRP.F exceeded the US Market which returned 22.3% over the past year.
Price Volatility
| CLRP.F volatility | |
|---|---|
| CLRP.F Average Weekly Movement | 15.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLRP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: CLRP.F's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 41 | Colin Biggin | www.claritypharmaceuticals.com |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.
Clarity Pharmaceuticals Ltd Fundamentals Summary
| CLRP.F fundamental statistics | |
|---|---|
| Market cap | US$665.26m |
| Earnings (TTM) | -US$20.01m |
| Revenue (TTM) | US$6.21m |
107.1x
P/S Ratio-33.3x
P/E RatioIs CLRP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLRP.F income statement (TTM) | |
|---|---|
| Revenue | AU$9.49m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$9.49m |
| Other Expenses | AU$40.05m |
| Earnings | -AU$30.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 100.00% |
| Net Profit Margin | -322.18% |
| Debt/Equity Ratio | 0% |
How did CLRP.F perform over the long term?
See historical performance and comparison